Resistance to Arsenic and Antimony-Based Drugs
2003
Resistance to Arsenic and Antimony-Based Drugs
publication
Evidence: moderate
Author Information
Author(s): Milena Salerno, Arlette Garnier-Suillerot
Primary Institution: Laboratoire de Physicochimie Biomoldculaire et Cellulaire (LPBC/CSSB UMR 7033), Université Paris Nord
Conclusion
Resistance to arsenic and antimony-based drugs is conferred by various mechanisms, including the overexpression of transport proteins that extrude these metalloids from cells.
Supporting Evidence
- Resistance to metalloid salts is found in bacteria, fungi, parasites, and animals.
- MRP1-overexpressing cells poorly accumulate arsenic and antimony due to enhanced cellular efflux.
- Leishmania strains resistant to pentavalent antimony and arsenite have been described.
Takeaway
Some germs and cancer cells can fight off medicines that use arsenic and antimony, making it hard to treat infections and diseases.
Limitations
The study does not provide specific experimental data or sample sizes, limiting the ability to generalize findings.
Want to read the original?
Access the complete publication on the publisher's website